Cantourage Group SE Reports Strong Q3 2025 Performance

Cantourage Group SE has announced robust business growth in the third quarter of 2025, with revenue increasing by 148% to EUR 75 million over the first nine months. Despite the challenging regulatory landscape in Germany, the company solidified its position in the European medical cannabis market.

Cantourage's Q3 revenues reached EUR 20.1 million, a considerable rise from EUR 13.2 million in the same period the previous year. The company also achieved an EBITDA of approximately EUR 3.9 million, showcasing operational efficacy.

International growth is evident, with market advances in the UK and strategic expansion in Poland. The company is also eyeing early opportunities in Spain and Italy. Innovation drives continued telemedicine offerings in Germany, preparing for upcoming regulatory shifts.

Looking forward, Cantourage is optimistic about further expansion, while remaining vigilant to market changes.